Chirwere cheAcute Lymphoblastic Leukemia (T-ALL)-08

Yesheng wekuFujian akati, "Dai ndaiziva nezveCAR-T kuBIOOCUS Medical Group, ndingadai ndauya kare."

MunaGunyana 2017, Yesheng akatanga mapundu kumeso, ayo akapararira zvishoma nezvishoma ndokuzobatana kuita mapenji. Pakazosvika Kukadzi 28, 2018, kuongororwa kwemapfupa kwakaratidza "acute T-cell lymphoblastic leukemia" mushure mekurapwa kakawanda nechemotherapy, pamwe nekuongororwa kwekusashanda zvakanaka nguva nenguva. Mishonga yese yakamiswa muna Chikumi 2019.

Muna Chivabvu 2021, Yesheng akaonekwa aine mamota akawanda munzvimbo yemuromo nepahuro uye mutsipa wakakura. Kuongororwazve kwemapfupa kwakaratidza kudzoka kwechirwere cheleukemia zvachose. Musi wa28 Chivabvu, Yesheng akatamisirwa kuDhipatimendi reChipiri reHematology kuti apinde. Mushure mekuongororwa kwakazara, kuongororwa kwacho kwakagadziriswa kuita "acute leukemia (T/myeloid biphenotypic)."

Kuongororwa kamwe chete kwechemotherapy hakuna kukonzera kuregererwa kwemapfupa emumongo. Musi wa27 Chikunguru, Yesheng akapihwa CD7 CAR-T cell infusion, zvichiteverwa nechemotherapy pamwe chete ne autologous CD7 CAR-T cell therapy. Mazuva gumi nemashanu mushure mekupihwa, kuongororwa kwemapfupa emumongo kwakaratidza kuti chirwere chacho chakanga chisina kunaka, uye hapana mhedzisiro yakaipa ye cytokine release syndrome (CRS) yegiredhi rekutanga uye hapana mhedzisiro yakaipa ye central nervous system.